Sematid 7 mg (Tablet)

Unit Price: ৳ 1,800.00 (1 x 10: ৳ 18,000.00)

Strip Price: ৳ 18,000.00

Medicine Details

Improves glycemic control in adults with type 2 diabetes mellitus
Reduces the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease
An adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients with obesity or overweight and weight-related comorbid conditions

GLP-1 analogue with 94% sequence as same as human GLP-1
Acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor
Reduces blood glucose in a glucose-dependent manner by stimulating insulin secretion and lowering glucagon secretion when blood glucose is high
Reduces body weight and body fat mass by an overall reduced appetite

Starter dose: 3 mg once daily for 30 days
Maintenance dose: 7 mg once daily for at least 30 days after the starter dose
Additional glycemic control dose: 14 mg once daily when needed
Starting dose for obesity: 0.25 mg once weekly for 4 weeks subcutaneously, with options for dose escalation and maintenance dose

Delays gastric emptying and can impact the rate of absorption of concomitantly administered oral medicinal products

Hypoglycemia when used with insulin or sulfonylurea
Frequent adverse reactions include gastrointestinal disorders, nausea, diarrhea, vomiting, abdominal pain, and constipation, which are generally mild or moderate in severity and of short duration

Should not be used during pregnancy
Should be discontinued at least 2 months before a planned pregnancy if a patient wishes to become pregnant
Should not be used during breastfeeding due to the risk to the breast-fed child

Should not be used in type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis
Should be discontinued promptly if pancreatitis is suspected and should not be restarted if pancreatitis is confirmed
Patients with diabetic retinopathy should be monitored

Safety and efficacy in children and adolescents below 18 years have not yet been established
No dose adjustment is required based on age or renal impairment
Not recommended for use in patients with end-stage renal disease
No dose adjustment is required for patients with hepatic impairment, but caution should be exercised

Overdose of up to 4 mg in a single dose and up to 4 mg in a week have been reported in clinical trials
Nausea is the most commonly reported adverse reaction in case of overdose
No specific antidote for overdose with Sematid
Appropriate supportive treatment should be initiated in the event of overdose according to the patient's clinical signs and symptoms
Dose adjustment considerations when adding Sematid to existing therapy of metformin, thiazolidinedione, sulfonylurea, or insulin
Guidance on missed dose administration